Celcuity Inc. Common Stock
Symbol: CELC (NASDAQ)
45.31
▼ (-8.41%) -4.160
Company Description:
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Key Stats
- Today's Open: $49.14
- Today's High: $51.655
- Today's Low: $45.31
- Today's Volume: 1.01M
- Yesterday Close: $49.47
- Yesterday High: $50.11
- Yesterday Low: $47.54
- Yesterday Volume: 859.23K
- Last Min Volume: 40
- Last Min High: $45.31
- Last Min Low: $45.31
- Last Min VWAP: $45.31
Company Profile
- Name: Celcuity Inc. Common Stock
- Website: https://www.celcuity.com
- Listed Date: 2017-09-20
- Location: MINNEAPOLIS, MN
- Market Status: Active
- CIK Number: 0001603454
- SIC Code: 8071
- SIC description: SERVICES-MEDICAL LABORATORIES
- Market Cap: $2.10B
- Round Lot: 100
- Outstanding Shares: 42.43M
- Asset Type: CS
RECENT FILINGS FOR CELC
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-23 | D/A | View |
| 2025-09-15 | 4 | View |
| 2025-09-10 | 4 | View |
| 2025-09-10 | 8-K | View |
| 2025-09-04 | 4 | View |
| 2025-08-20 | 4 | View |
| 2025-08-20 | 4 | View |
| 2025-08-20 | 4 | View |
| 2025-08-18 | SCHEDULE 13D/A | View |
| 2025-08-14 | 10-Q | View |
| 2025-08-14 | 8-K | View |
| 2025-08-04 | SCHEDULE 13G | View |
| 2025-08-04 | SCHEDULE 13G/A | View |
| 2025-08-01 | 3 | View |
| 2025-08-01 | SCHEDULE 13D | View |
| 2025-08-01 | 8-K | View |
| 2025-07-31 | 305B2 | View |
| 2025-07-31 | 8-K | View |
| 2025-07-31 | 424B5 | View |
| 2025-07-31 | 424B5 | View |
Latest News on CELC